100 results found.

Adult Primary Hepatocellular Carcinoma, Localized Unresectable Ad Clinical Trial using sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.
sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C

Carcinoma, Hepatocellular Clinical Trial using TACE (transarterial chemoembolization); Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib.
TACE (transarterial chemoembolization); Sorafenib (Nexavar, BAY43-9006)

Metastatic Colorectal Cancer, Metastatic Gastric Cancer, Metastat Clinical Trial using CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers.
CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine

Carcinoma, Hepatocellular Clinical Trial using Nintedanib high dose; Nintedanib low dose; Nintedanib medium dose

Boehringer Ingelheim - Recruiting 20 years or older.
- An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma..
Nintedanib high dose; Nintedanib low dose; Nintedanib medium dose

Hepatocellular Carcinoma Clinical Trial using Cabozantinib (XL184); Placebo

Exelixis - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib.
Cabozantinib (XL184); Placebo

Liver Cancer Clinical Trial using yttrium Y 90 glass microspheres; Cisplatin; Mitomycin; Doxorubicin

Northwestern University - Recruiting 18 years or older.
- An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial).
yttrium Y 90 glass microspheres; Cisplatin; Mitomycin; Doxorubicin

Carcinoma, Hepatocellular Clinical Trial using Everolimus; Tacrolimus; Myfortic; CellCept

Baylor Research Institute - Recruiting 18 years or older.
- A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria.
Everolimus; Tacrolimus; Myfortic; CellCept

Solid Cancers Clinical Trial using Vismodegib

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function.
Vismodegib

Hepatocellular Carcinoma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects With or Without Chronic Viral Hepatitis.
Nivolumab

Carcinoma, Hepatocellular Clinical Trial using LY2157299; Sorafenib

Eli Lilly and Company - Recruiting 18 years or older.
- Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma.
LY2157299; Sorafenib

Cancer Metastatic to the Liver, Hepatocellular Carcinoma That is Clinical Trial using PV-10 (10% rose bengal disodium)

Provectus Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.
PV-10 (10% rose bengal disodium)

Carcinoma, Hepatocellular Clinical Trial using Refametinib (BAY86-9766)

Bayer - Recruiting 18 years or older.
- A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC).
Refametinib (BAY86-9766)

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Li Clinical Trial using yttrium Y 90 glass microspheres; laboratory biomarker analysis

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Humanitarian Device Exemption Treatment Protocol of TheraSpherer For Treatment of Unresectable Hepatocellular Carcinoma.
yttrium Y 90 glass microspheres; laboratory biomarker analysis

Hepatocellular Carcinoma Clinical Trial using HepaSphere/QuadraSphere Microspheres; PVA, lipiodol, doxorubicin

Merit Medical Systems, Inc. - Recruiting 18 years or older.
- Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma.
HepaSphere/QuadraSphere Microspheres; PVA, lipiodol, doxorubicin

Adult Primary Hepatocellular Carcinoma, Adult Primary Undifferent Clinical Trial using sorafenib tosylate; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting N/A or older.
- Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC.
sorafenib tosylate; laboratory biomarker analysis

Carcinoma, Hepatocellular Clinical Trial

National Taiwan University Hospital - Recruiting 20 years or older.
- Combination of Dynamic Contrast-enhanced and Diffusion-weighted Imaging and Magnetic Resonance Spectroscopy in 3T MRI to Early Predict Treatment Efficacy in Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma.

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Pain, Postoperative, or Hepatocellular Carcinoma Clinical Trial using Pregabalin; Placebo (for Pregabalin)

Eastern Hepatobiliary Surgery Hospital - Recruiting 18 years to 70 years.
- A Randomized Placebo-Controlled Study of Whether Pre-operative Pregabalin 150 mg Will Improve Pain Control in Patients With Hepatocellular Carcinoma Undergoing Partial Hepatectomy.
Pregabalin; Placebo (for Pregabalin)

Liver Cell Caricinoma, Liver Cancer, or Hepatocellular Carcinoma Clinical Trial using Tremelimumab; Trans-Arterial Cather Chemoembolization; Radiofrequency Ablation (RFA)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of Tremelimumab, A Monoclonal Antibody Against CTLA-4, in Combination With Either Trans-Arterial Catheter Chemoembolization (TACE) or Radiofrequency Ablation (RFA) in Subjects With Hepatocellular Carcinoma (HCC).
Tremelimumab; Trans-Arterial Cather Chemoembolization; Radiofrequency Ablation (RFA)

Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area.

Hepatocellular Carcinoma Clinical Trial using Sorafenib; Doxorubicin

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib.
Sorafenib; Doxorubicin

Advanced Adult Hepatocellular Carcinoma, or Hepatocellular Carcin Clinical Trial using AZD9150

AstraZeneca - Recruiting 18 years or older.
- A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma.
AZD9150

Hepatocellular Carcinoma Clinical Trial using Vitamin B-6; Coenzyme Q10; Vitamin B-6+Coenzyme Q10; Placebo

Taichung Veterans General Hospital - Recruiting 20 years to 80 years.
- .
Vitamin B-6; Coenzyme Q10; Vitamin B-6+Coenzyme Q10; Placebo

Hepatocellular Carcinoma Clinical Trial using MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

SYZ Cell Therapy Co.. - Recruiting 20 years to 70 years.
- Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens.
MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

Hepatocellular Carcinoma Clinical Trial using everolimus; everolimus placebo

Novartis - Recruiting 18 years or older.
- A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitorr) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study.
everolimus; everolimus placebo

Confirmed Diagnosis of HCC;, Patients Who Are Scheduled to Underg Clinical Trial using TACE or Systemic Therapy

Chinese University of Hong Kong - Recruiting 18 years or older.
- A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Unresectable Hepatocellular Carcinoma.
TACE or Systemic Therapy

Unresectable Hepatocellular Carcinoma With Portal Vein Thrombosis Clinical Trial using TheraSphere; Sorafenib

BTG International Inc. - Recruiting 18 years or older.
- A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSpherer) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT).
TheraSphere; Sorafenib

Hepatocellular Carcinoma Clinical Trial using TACE with Hyperthermia Treatment

Chinese University of Hong Kong - Recruiting 18 years to 75 years.
- A Pilot Study on the Feasibility of Combined Chemoembolization and Adjuvant Systemic Hyperthermia for Palliative Treatment of Unresectable Hepatocellular Carcinoma(HCC).
TACE with Hyperthermia Treatment

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Li Clinical Trial using tivozanib; pharmacological study; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma.
tivozanib; pharmacological study; laboratory biomarker analysis

Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, or Carcinoma, Hep Clinical Trial using TRC 105; Sorafenib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC).
TRC 105; Sorafenib

Unresectable Hepatocellular Carcinoma Clinical Trial using TheraSphere

BTG International Inc. - Recruiting 18 years or older.
- A Phase III Clinical Trial of Intra-arterial TheraSpherer in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC).
TheraSphere

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma).
Sorafenib (Nexavar, BAY43-9006)

Carcinoma, Hepatocellular Clinical Trial using Regorafenib (BAY73-4506); Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib.
Regorafenib (BAY73-4506); Placebo

Metastatic Hepatocellular Carcinoma, or Advanced Liver Cancer Clinical Trial using Ascorbic Acid + Sorafenib; Sorafenib alone

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma.
Ascorbic Acid + Sorafenib; Sorafenib alone

Carcinoma, Hepatocellular Clinical Trial using Refametinib (BAY86-9766); Sorafenib (BAY43-9006)

Bayer - Recruiting 18 years or older.
- A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC).
Refametinib (BAY86-9766); Sorafenib (BAY43-9006)

Liver Cancer Clinical Trial using onartuzumab; sorafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB GIVEN AS A SINGLE AGENT AND IN COMBINATION WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
onartuzumab; sorafenib

Hepatocellular Carcinoma Clinical Trial using No Intervention

Bayer - Recruiting 18 years or older.
- Profile of the Hepatocellular Carcinoma Patients in Turkey.
No Intervention

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma.
Sorafenib (Nexavar, BAY43-9006)

Hepatocellular Carcinoma, Hepatocellular Cancer, or Carcinoma, He Clinical Trial using TRC105

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 80 years.
- A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib.
TRC105

Carcinoma, Hepatocellular, or Carcinoma, Renal Cell Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- Regulatory Post Marketing Surveillance Study on Nexavarr.
Sorafenib (Nexavar, BAY43-9006)

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 18 years or older.
- Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent.
Sorafenib (Nexavar, BAY43-9006)

Hepatocellular Carcinoma Clinical Trial using SGI-110

Astex Pharmaceuticals - Recruiting 18 years or older.
- A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib.
SGI-110

Hepatocellular Carcinoma Clinical Trial using TACE+EBRT; Sorafenib

Asan Medical Center - Recruiting 20 years or older.
- Randomized Phase II Trial Comparing Transarterial Chemoembolization Plus External Beam Radiotherapy Versus Sorafenib in Patients With Hepatocellular Carcinoma With Major Vascular Invasion.
TACE+EBRT; Sorafenib

Carcinoma, Hepatocellular Clinical Trial using PF-03446962; Best Supportive Care; Best supportive care

Pfizer - Recruiting 18 years or older.
- A Phase 2, Randomized, Open Label Study To Evaluate The Efficacy, Safety, Pharmacodynamics, Pharmacokinetics Of The Anti-ALK-1 MAB PF-03446962 In Combination With Best Supportive Care VS. Best Supportive Care Alone In Adult Patients With Advanced Hepatocellular Carcinoma.
PF-03446962; Best Supportive Care; Best supportive care

Carcinoma Hepatocellular Clinical Trial using RT and hyperthermia after TACE

Samsung Medical Center - Recruiting 20 years or older.
- Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis: Prospective Phase II Trial.
RT and hyperthermia after TACE

Liver Cancer Clinical Trial using doxorubicin-eluting beads; everolimus; placebo

Swiss Group for Clinical Cancer Research - Recruiting 18 years or older.
- A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolization (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma.
doxorubicin-eluting beads; everolimus; placebo

Localized Non-Resectable Adult Hepatocellular Carcinoma Clinical Trial using Stereotactic body radiotherapy

Samsung Medical Center - Recruiting 20 years or older.
- Effectiveness and Safety of the Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prospective Phase II Trial.
Stereotactic body radiotherapy

Hepatocellular Carcinoma Clinical Trial

Peking Union Medical College Hospital - Recruiting 18 years to 80 years.
- Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma..

Carcinoma, Hepatocellular Clinical Trial using Stereotactic Body Radiation

Indiana University - Recruiting 18 years or older.
- Multi-institution Phase I/II Dose Escalation Study of Hypofractionated Stereotactic Body Radiation Therapy for Primary Hepatocellular Carcinoma.
Stereotactic Body Radiation

Liver Cancer Clinical Trial using ARQ197; Placebo

Kyowa Hakko Kirin Company, Limited - Recruiting 20 years or older.
- A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy.
ARQ197; Placebo

Advanced Hepatocellular Carcinoma, HCC, or Liver Cancer Clinical Trial using PD-0332991

Thomas Jefferson University - Recruiting 18 years or older.
- A Phase II Study of PD-0332991 in Adult Patients With Advanced Hepatocellular Carcinoma.
PD-0332991

Hepatocellular Carcinoma, Clinical Trial using TACE; TACE+ RTC

Nantes University Hospital - Recruiting 18 years or older.
- Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.
TACE; TACE+ RTC

Hepatocellular Carcinoma Clinical Trial using AG-013736

National Taiwan University Hospital - Recruiting 18 years or older.
- Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma.
AG-013736

Liver Cancer Clinical Trial using Lenalidomide

National Taiwan University Hospital - Recruiting 20 years or older.
- Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial.
Lenalidomide

Unresectable Non-metastatic Hepatocellular Carcinoma, or Child A/ Clinical Trial using Zavedosr; Blood samples

Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older.
- LIDA-B: Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedosr): Phase I Study.
Zavedosr; Blood samples

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- Study of Unresectable HCC Treated Concomitantly With TACE and Sorafenib in Chinese Patients.
Sorafenib (Nexavar, BAY43-9006)

Advanced Adult Hepatocellular Carcinoma Clinical Trial using Best Supportive Care; sorafenib

National Cancer Institute, Naples - Recruiting 18 years or older.
- Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial.
Best Supportive Care; sorafenib

Liver Cancer Clinical Trial using Sorafenib; Yttrium-90 Microspheres; Follow-Up Phone Calls

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C.
Sorafenib; Yttrium-90 Microspheres; Follow-Up Phone Calls

Hepatocellular Carcinoma Clinical Trial using Sirolimus; m-TOR inhibitor free

Seoul National University Hospital - Recruiting 18 years to 80 years.
- A Randomized Phase ?, Trial With Sirolimus-containing Versus mTOR-inhibitor Free Immunosuppression in Patients Undergoing Living Donor Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria.
Sirolimus; m-TOR inhibitor free

Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Pre Clinical Trial using sorafenib tosylate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 30 years.
- A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma.
sorafenib tosylate; pharmacological study; laboratory biomarker analysis

Hepatocellular Carcinoma Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 18 years or older.
- Sorafenib Treatment Modalities for HEpatoceLLular Carcinoma Patients in ItAly.
Sorafenib (Nexavar, BAY43-9006)

Hepatocellular Carcinoma Clinical Trial using Liver resection

Seoul National University Hospital - Recruiting 20 years to 80 years.
- Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for Patients With Hepatocellular Carcinoma.
Liver resection

Hepatocellular Carcinoma Clinical Trial using Drug-Eluting Beads (DEB) with Doxorubicin; Lipiodol Ethanol Mixture (LEM)

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma.
Drug-Eluting Beads (DEB) with Doxorubicin; Lipiodol Ethanol Mixture (LEM)

Hepatocellular Carcinoma Clinical Trial using transarterial radioembolization (TARE); transarterial chemoembolization (TACE)

Seoul National University Hospital - Recruiting 20 years to 80 years.
- A Randomized, Multi-center, Open Label, Phase 3 Trial Comparing Conventional TACE and Transarterial Radioembolization in Patients With Unilobar Advanced Hepatocellular Carcinoma.
transarterial radioembolization (TARE); transarterial chemoembolization (TACE)

Liver Cancer Clinical Trial using bevacizumab; erlotinib hydrochloride; sorafenib tosylate

Medical University of South Carolina - Recruiting 18 years or older.
- A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC).
bevacizumab; erlotinib hydrochloride; sorafenib tosylate

Hepatocellular Carcinoma, or Liver Cirrhosis Clinical Trial using Sirsphere trans-arterial radioembolization

Jules Bordet Institute - Recruiting 18 years or older.
- Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver.
Sirsphere trans-arterial radioembolization

Carcinoma, Hepatocellular Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 18 years or older.
- International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC).
Sorafenib (Nexavar, BAY43-9006)

Hepatocellular Carcinoma Clinical Trial using COMBIG-DC

Immunicum AB - Recruiting 18 years or older.
- A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma.
COMBIG-DC

Liver Cancer Clinical Trial using yttrium Y 90 glass microspheres

Northwestern University - Recruiting 18 years or older.
- A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma.
yttrium Y 90 glass microspheres

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Li Clinical Trial using stereotactic body radiation therapy

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- A Pilot Study of Stereotactic Liver Irradiation for Hepatocellular Carcinoma.
stereotactic body radiation therapy

Hepatocellular Carcinoma, or Esophageal Cancer Clinical Trial

National Taiwan University Hospital - Recruiting 20 years to 90 years.
- Serum Biomarker Study for the Prognosis of Patients With Hepatocellular Carcinoma and Esophageal Cancer Undergoing Radiotherapy Using Multiplex Proximity Ligation Assay.

Hepatocellular Carcinoma, Metastasis, or Invasion Clinical Trial using Colchicine

Kaohsiung Medical University Chung-Ho Memorial Hospital - Recruiting 20 years to 90 years.
- Evaluation the Potential of Colchicine for the Palliative Management of Hepatocellular Carcinoma Patients With Distant Metastasis or Large Vessel Invasion.
Colchicine

Oral Mucositis, Renal Cell Carcinoma, Hepatocellular Carcinoma, o Clinical Trial using supersaturated calcium-phosphate rinse; sodium chloride 0.9 %

Waterland Hospital - Recruiting 18 years or older.
- Phase III Randomized Double-blind Cross-over Trial of Caphosolr Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy.
supersaturated calcium-phosphate rinse; sodium chloride 0.9 %

Hepatocellular Carcinoma Clinical Trial using TACE-DEB; 90Y-RE

University Hospital, Ghent - Recruiting 18 years or older.
- Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial (TRACE Trial).
TACE-DEB; 90Y-RE

Hepatocellular Carcinoma Clinical Trial using Laparoscopic liver resection; Open liver resection

Sir Run Run Shaw Hospital - Recruiting 18 years to 70 years.
- A Randomized Controlled Trial of Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular Carcinoma.
Laparoscopic liver resection; Open liver resection

Unresectable or Metastatic Hepatocellular Carcinoma Clinical Trial using Temsirolimus

University of Tennessee Cancer Institute - Recruiting 18 years or older.
- A Phase II Study of Temsirolimus as Second-line Therapy in Patients With Advanced, Unresectable Hepatocellular Carcinoma.
Temsirolimus

Cancer of Liver Clinical Trial using radiofrequency ablation associated with TACE; radiofrequency ablation only

Southwest Hospital, China - Recruiting 18 years to 75 years.
- Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation Associated With Postoperative Transhepatic Arterial Chemoembolization--a Prospective Randomized Clinical Trial.
radiofrequency ablation associated with TACE; radiofrequency ablation only

Hepatocellular Carcinoma, or Liver Cancer Clinical Trial using Microwave Ablation

St. Joseph Hospital of Orange - Recruiting 18 years or older.
- Microwave Ablation of Resectable Liver Tumors.
Microwave Ablation

Hepatocellular Carcinoma Clinical Trial using Oral; Supportive

All India Institute of Medical Sciences, New Delhi - Recruiting 12 years to 70 years.
- RCT Of Oral Thalidomide And Capecitabine Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma (BCLC D).
Oral; Supportive

Liver Cirrhosis, or Carcinoma, Hepatocellular Clinical Trial

Asan Medical Center - Recruiting 20 years to 80 years.
- Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver: Prospective Pathologic Correlation With Explanted Liver.

Hepatocellular Carcinoma, or Renal Cell Carcinoma Clinical Trial

Samsung Medical Center - Recruiting N/A or older.
- Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma.

Hepatocellular Carcinoma Clinical Trial using LC Bead loaded with doxorubicin

University of Pittsburgh - Recruiting 18 years or older.
- LC Drug Eluting Bead for Regional Chemoembolization to Downstage Unresectable Hepatocellular Carcinoma (HCC) to Liver Transplantation.
LC Bead loaded with doxorubicin

Hepatocellular Carcinoma, Liver Cirrhosis, Hepatitis B, or Hepati Clinical Trial using CE-US (SonazoidT); B-mode US

Japan Liver Oncology Group - Recruiting 20 years or older.
- Sonazoid Enhanced Liver Cancer Trial for Early Detection.
CE-US (SonazoidT); B-mode US

Carcinoma, Hepatocellular Clinical Trial using Operation

Far Eastern Memorial Hospital - Recruiting 18 years to 75 years.
- Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis.
Operation

Hepatocellular Carcinoma Clinical Trial using RAD001

Massachusetts General Hospital - Recruiting 18 years or older.
- A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma.
RAD001

Carcinoma, Hepatocellular Clinical Trial using Transcatheter Arterial Chemoembolization (TACE); Transcatheter Arterial Pegylated Interferon Embolization (TAIE)

Hospital Authority, Hong Kong - Recruiting 18 years or older.
- A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma.
Transcatheter Arterial Chemoembolization (TACE); Transcatheter Arterial Pegylated Interferon Embolization (TAIE)

Hepatocellular Cancer Clinical Trial

South West Sydney Local Health District - Recruiting 18 years or older.
- Phase 2 Study of Measurement of Trough Levels of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Liver Cirrhosis Clinical Trial

National Taiwan University Hospital - Recruiting 50 years to 70 years.
- Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4).

Carcinoma, Hepatocellular Clinical Trial using Thalidomide(THADO), Tegafur/Uracil(UFUR)

Far Eastern Memorial Hospital - Recruiting 18 years or older.
- .
Thalidomide(THADO), Tegafur/Uracil(UFUR)

Hepatocellular Carcinoma, or Liver Cancer Clinical Trial using Radiofrequency ablation; TACE

Sun Yat-sen University - Recruiting 18 years to 75 years.
- Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma.
Radiofrequency ablation; TACE

Hepatocellular Carcinoma Clinical Trial using sustained released 5-FU and sustained released cisplatin; sustained released 5-FU; TACE

Eastern Hepatobiliary Surgery Hospital - Recruiting 18 years to 75 years.
- Clinical Randomized Control Trial of Intraoperative Implanting Chemotherapeutic Drugs Sustained Release Following Resection of Hepatocellular Carcinoma Against Postoperative Short-Term Recurrence.
sustained released 5-FU and sustained released cisplatin; sustained released 5-FU; TACE

Hepatocellular Carcinoma Clinical Trial using mitomycin, Fluorouracil

Shenzhen Kangzhe Pharmaceutical Co., Ltd. - Recruiting 18 years to 75 years.
- A Randomized, Double Blind, Placebo Controled, Multicenter Phase ?Study to Evaluate the Safety and Efficacy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients.
mitomycin, Fluorouracil

Hepatocellular Carcinoma Clinical Trial using sirolimus

Fudan University - Recruiting 18 years to 75 years.
- A Prospective Randomised, Open-Labeled Study Comparing Sirolimus Versus FK506 In OLT for Patients With HCC Exceeding Milan Criteria.
sirolimus

Hepatocellular Carcinoma Clinical Trial using Thymopentin

Fudan University - Recruiting 18 years to 75 years.
- Phase III Study of Thymopentin in Patients After Curative Resection of Small.
Thymopentin

Colorectal Cancer, Liver Neoplasms, Hepatocellular Carcinoma, Gal Clinical Trial using interventionally implanted hepatic arterial port catheter

Charite University, Berlin, Germany - Recruiting 18 years or older.
- Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms..
interventionally implanted hepatic arterial port catheter

Hepatocellular Carcinoma, Hepatitis B, or Hepatitis C Clinical Trial

National Taiwan University Hospital - Recruiting N/A or older.
- Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by Surface-Enhanced Laser Desorption/Ionization (SELDI).

Hepatocellular Carcinoma Clinical Trial

National Taiwan University Hospital - Recruiting 18 years to 90 years.
- Identification of Differentially Expressed Genes in Hepatocellular Carcinoma With DNA Microarrays.